AU9069291A - Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function - Google Patents

Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function

Info

Publication number
AU9069291A
AU9069291A AU90692/91A AU9069291A AU9069291A AU 9069291 A AU9069291 A AU 9069291A AU 90692/91 A AU90692/91 A AU 90692/91A AU 9069291 A AU9069291 A AU 9069291A AU 9069291 A AU9069291 A AU 9069291A
Authority
AU
Australia
Prior art keywords
angiotensin
medicament
preparation
receptor antagonists
cognitive function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU90692/91A
Inventor
James Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU9069291A publication Critical patent/AU9069291A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU90692/91A 1990-12-14 1991-12-12 Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function Abandoned AU9069291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027197A GB9027197D0 (en) 1990-12-14 1990-12-14 Medicaments
GB9027197 1990-12-14

Publications (1)

Publication Number Publication Date
AU9069291A true AU9069291A (en) 1992-07-08

Family

ID=10687033

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90692/91A Abandoned AU9069291A (en) 1990-12-14 1991-12-12 Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function

Country Status (5)

Country Link
EP (1) EP0561896A1 (en)
JP (1) JPH06503338A (en)
AU (1) AU9069291A (en)
GB (1) GB9027197D0 (en)
WO (1) WO1992010186A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0577025A3 (en) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-ii-receptorantagonist for the treatment and prophylaxis of coronary heart diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EA201592263A1 (en) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. ULTRASCULAR AGONISTS OF GUANYLACYCLASE C, METHOD OF THEIR RECEIVING AND USING

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
CA2018438C (en) * 1989-06-14 2000-08-08 Joseph Alan Finkelstein Imidazolyl-alkenoic acids
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists

Also Published As

Publication number Publication date
EP0561896A1 (en) 1993-09-29
WO1992010186A1 (en) 1992-06-25
JPH06503338A (en) 1994-04-14
GB9027197D0 (en) 1991-02-06

Similar Documents

Publication Publication Date Title
AU8374491A (en) Angiotensin II receptor antagonists
AU3665793A (en) Fibrinogen receptor antagonists
AU4396193A (en) 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
AU8477891A (en) Fibrinogen receptor antagonists
AU6062590A (en) Pharmaceutically active compounds
AU5194496A (en) 5-HT4 receptor antagonists
AU3920693A (en) Four novel receptors of the TGF-beta receptor family
AU5093293A (en) Alicyclic compounds as tachykinin receptor antagonists
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
GB9020051D0 (en) Muscarinic receptor antagonists
AU3276293A (en) Angiotensin II receptor antagonists
EP0711559A3 (en) Use of phosphatidylserines for the manufacture of a medicament for improving cerebration
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
EP0488959A3 (en) New uses of competitive nmda receptor antagonists
AU3949889A (en) The reductive amination of hydroxy-containing compounds
AU1784992A (en) Subunit of the human interleukin-3 receptor
AU8720791A (en) Disposable dispenser for powder
AU9069291A (en) Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function
AU4377793A (en) Alternative receptor therapy
AU3981989A (en) Improved eyedrop dispenser
AU1919992A (en) Angiotensin ii receptor antagonist thiazole devivatives
AU5322994A (en) Fibrinogen receptor antagonists
AU1583492A (en) Use of sigma receptor antagonists for treatment of amphetamine abuse
AU8225391A (en) The use of inositolmonophosphate for the preparing of a medicament effective as a neuropeptide gamma-antagonist
AU9064191A (en) Use of angiotensin ii receptor antagonists in the treatment of atheroma